Stories about Systematic review

Subscribe to topic

Subscribe to Systematic review

08.11.2019 – 10:00
Fresenius Kabi Deutschland GmbH
Omega-3 fatty-acid enriched parenteral nutrition improves patient outcomes
BAD HOMBURG, GERMANY (ots) - A new systematic literature review and meta-analysis1 confirms and extends previous results that omega-3 (omega-3) fatty-acid enriched parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients. Including a total of 49 randomized controlled trials (RCTs), this literature review provides the most ...
more
23.10.2019 – 16:23
UEG Week
UEG Week Exhibition Celebrates 50 Years of Colonoscopy in Preventing and Diagnosing Gastrointestinal Diseases, Including Colorectal Cancer
Barcelona, Spain (ots/PRNewswire) - An interactive exhibition celebrating the 50th anniversary since the completion of the first successful colonoscopy has been launched at the United European Gastroenterology (UEG) Week in Barcelona. The educational exhibition is jointly supported by Norgine, Fujifilm and Olympus ...
more
01.10.2019 – 19:39
Novo Nordisk A/S
Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim of improving the lives of people living with obesity. The collaboration ...
more
25.09.2019 – 08:01
ETHICON, INC.
Ethicon Launches New Powered Circular Stapler With Dual Technologies to Reduce Anastomotic Complications in Colorectal, Gastric, and Thoracic Surgery
Vienna (ots/PRNewswire) - Innovative technology helps address critical challenge of anastomotic leaks which can occur in up to 8.6% of colorectal surgeries1,11% in oesophagectomies2 and 4% in gastrectomies3 Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the launch of the ECHELON ...
more
24.06.2019 – 14:00
Merck KGaA
Merck to Showcase New Data Across MS Portfolio at EAN 2019
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK or U.S. based media - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...
more
15.04.2019 – 10:00
Galderma
#RosaceaNoFilter: Online Influencers Take the Lead in Raising Rosacea Awareness in Galderma's Empowering Rosacea Awareness Month Social Media Campaign
Lausanne, Switzerland (ots/PRNewswire) - As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share experiences of the beyond ...
more
04.04.2019 – 14:47
Norgine
Norgine New Study Highlights Need to Increase Public Understanding of Important Role of Colonoscopy in Preventing and Diagnosing Gastrointestinal Diseases, Including Colorectal Cancer
Amsterdam (ots) - - Those with no previous experience of colonoscopy were considerably more nervous about the procedure than those who had already undergone colonoscopy (74% vs 49%) - Current lack of public understanding around ...
more
Multimedia News Release
03.01.2019 – 08:01
NORGINE B.V. and KOREA PHARMA CO., LTD.
NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea
Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...
more
20.12.2018 – 16:01
Merck KGaA
Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - European Medicine Agency (EMA) grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer (BTC) - EMA orphan drug designation for M7824 in ...
more
28.11.2018 – 13:34
LEH Pharma
New Data Indicate That EyeMax Mono, a Lens Tailored Specifically for Patients With Dry Age-related Macular Degeneration (AMD), Offers Significant Improvement in Visual Function
London (ots/PRNewswire) - EyeMax Mono implantation results in an improved mean visual acuity of 18 ETDRS letters and 57% increase in mean reading speed LEH Pharma Ltd, a leading provider of innovative technologies for macular disorders, today announces new data published in the Journal of Refractive Surgery[1], ...
more
06.11.2018 – 09:02
Primary Care Diabetes Europe (PCDE)
Primary Care Diabetes Europe Issues Call to Action Against Clinical Inertia in the Treatment of Type-2 Diabetes
Ekeren, Belgium (ots/PRNewswire) - Research identifies lack of primary care physician adherence to treatment guidelines among the challenges to optimal care for patients with type-2 diabetes Primary Care Diabetes Europe (PCDE) today issued a call to action challenging primary care physicians and other healthcare ...
more
09.10.2018 – 08:01
Merck KGaA
Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF β-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: ...
more
29.06.2018 – 01:02
Astellas Pharma Europe Limited
Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine
Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...
more

1